Loading clinical trials...
Loading clinical trials...
A Phase 3 Clinical Trial of Pembrolizumab (MK-3475) in First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Conditions
Interventions
Pembrolizumab
Cisplatin
+3 more
Start Date
March 19, 2015
Primary Completion Date
February 25, 2019
Completion Date
July 19, 2023
Last Updated
July 18, 2025
NCT05980000
NCT03691714
NCT04969861
NCT00088907
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions